Sunovion to Present New Clinical Data on Brovana, a COPD Inhalation Therapy, at ATS 2016

Patrícia Silva, PhD avatar

by Patrícia Silva, PhD |

Share this article:

Share article via email
Trelegy Ellipta for COPD

Sunovion Pharmaceuticals, Inc., will present new clinical and health outcomes data for its Brovana (arformoterol tartrate) Inhalation Solution at the 2016 American Thoracic Society International Conference (ATS 2016), taking place May 13–18 in San Francisco, California.

At the ATS meeting, Sunovion will present post-hoc analyses of clinical data generated from its long-term safety study of Brovana in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The company will also present results from a prospective health outcomes study investigating the prevalence of low peak inspiratory flow rate among  COPD patients.

“COPD is a chronic and progressive disease affecting more than 15 million adults in the U.S. and is the third leading cause of death in the U.S.,” Krithika Rajagopalan, vice president, head of Global Health Economics and Outcomes Research at Sunovion, said in apress release. “COPD exacerbations adversely impact a person’s quality of life, and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD.”

The company’s presentations at ATS 2016 are:

  • Poster #A6833, “Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate,” will be presented on May 18, at 11:00 a.m.–12:45 p.m.
  • Poster #A1122, “Chronic Obstructive Pulmonary Disease (COPD) — Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study,” will be presented on May 15, at 9:00 a.m.–11:00 a.m.
  • Poster Board #A1506, “Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic Obstructive Pulmonary Disease (COPD) Patients At Discharge After an Exacerbation,” will be presented on May 15, at 11:00 a.m.–12:45 p.m.

Brovana Inhalation Solution is a long-acting β2 adrenoreceptor agonist (LABA) used as a long-term (maintenance) therapy to prevent and decrease shortness of breath and wheezing in patients with COPD. Brovana belongs to a class of drugs known as bronchodilators, and works in the airways by opening breathing passages and relaxing muscles.